It is possible that the concurrent enhancement of SKP2 and FOXA1 protein levels typically detected in PCa is due to mutations in the C‐TAD domain of FOXA1 which may affect SKP2‐recognition and degradation of FOXA1. Here, SKP2 is linked to posterior cortical atrophy.